Prostate Cancer Outcomes in Patients Living With HIV/AIDS Treated With Radiation Therapy: A Systematic Review.
Prostate Cancer Outcomes in Patients Living With HIV/AIDS Treated With Radiation Therapy: A Systematic Review.
复制标题
DOI：
10.1016/j.adro.2022.101074
复制
发表时间：
2023-01
影响因子：
2.3
通讯作者：
Goyal, Sharad
中科院分区：
文献类型：
--
作者：
Vaziri, Tina;Rao, Yuan J;Whalen, Michael;Bethony, Jeffrey;Lin, Jianqin;Goyal, Sharad
关于艾滋病毒/艾滋病（PLWHA）感染者前列腺癌（PCa）的治疗和结局尚未达成共识。本系统综述旨在总结在诊断为PCa的PLWHA患者中采用放射治疗（RT）管理PCa的证据。于2021年9月在PubMed、科克伦图书馆和Scopus数据库中使用系统性综述和荟萃分析的首选报告项目（PRISMA）标准进行了检索。纳入报告PLWHA经明确RT治疗PCa的结局的文章。共有9项研究（187例确诊为PCa的HIV患者）符合入选标准。HIV感染至PCa诊断的持续时间为8.5至18.6年，69%至100%的患者在诊断时接受高效抗逆转录病毒治疗。患者的前列腺特异性抗原水平范围为8至82 ng/mL。大多数患者（59%）接受了体外放射治疗，其次是近距离放射治疗（20.5%）。3项研究报告的4年或5年无生化失败率在87%至97%之间，2项研究报告的5年癌症特异性生存率为84%至97%。使用不良事件通用术语标准，3项研究报告了毒性，仅在2例患者中观察到3级毒性。RT在PLWHA中有效且耐受性良好，这得到了与一般人群相当的生化控制、临床结局和死亡率以及轻度放射毒性报告的支持。关于RT对CD 4计数和病毒载量的影响，有混合的证据，需要进一步的研究来更好地了解这种关系。这些发现支持在PLWHA伴PCa患者中使用确定性RT。
A consensus has not been reached regarding the treatment and outcomes of prostate cancer (PCa) in people living with HIV/AIDS (PLWHA). This systematic review aims to summarize the evidence on the management of PCa with radiation therapy (RT) in PLWHA diagnosed with PCa. Searches were conducted in the PubMed, Cochrane Library, and Scopus databases during September 2021 using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. Articles reporting on outcomes of PLWHA treated for PCa with definitive RT were sought for inclusion. A total of 9 studies with 187 patients with HIV who received diagnoses of PCa met inclusion criteria. The duration of HIV infection to PCa diagnosis ranged from 8.5 to 18.6 years with 69% to 100% of patients on highly active antiretroviral therapy at the time of diagnosis. Patients’ prostate-specific antigen levels ranged from 8 to 82 ng/mL. The majority of patients (59%) were treated with external beam RT, followed by brachytherapy (20.5%). The 4- or 5-year biochemical failure–free rate was reported to be between 87% and 97% in 3 studies, and 2 studies reported an 84% to 97% 5-year cancer-specific survival. Using Common Terminology Criteria for Adverse Events criteria, 3 studies reported toxicities and grade 3 toxicity was observed in only 2 patients. RT is efficacious and well tolerated in PLWHA as supported by the comparable biochemical control, clinical outcome, and mortality to the general population as well as by the mild reports of radiotoxicity. There is mixed evidence regarding the effect of RT on CD4 count and viral load, and further studies are needed to better understand this relationship. These findings support the use of definitive RT in PLWHA with PCa.
影响因子：
1.4
作者：
Martínez E;Garin O;Pardo Y;Fernández P;Guix B;Gutiérrez C;Boladeras A;Ferrer F;Hernández T;Ayala A;Egiguren M;Fernández G;Muñoz V;Macías V;Pera J;Pont À;Ferrer M;Guedea F;Multicentric Spanish Group of Clinically Localized Prostate Cancer;Multicentric Spanish Group of Clincally Localized Prostate Cancer: Montse Ferrer, Àngels Pont, Olatz Garin, Yolanda Pardo, Jordi Alonso, Mónica Ávila, Víctor Zamora, Ferran Guedea, Montse Ventura, Cristina Gutiérrez, Ferran Ferrer, Ana Boladeras, José Francisco Suárez, Manel Castells, Xavier Bonet, Pastor S, Carmen Bonet, Gemma Sancho, Javier Ponce de León, Joan Palou, Belén de Paula, Alai Goñi, Pablo Fernández, Ismael Herruzo, Asunción Hervás, Alfredo Ramos, Víctor Macías, Josep Solé, Marta Bonet, Alfonso Mariño, Patricia Cabrera, Maria José Ortiz
通讯作者：
Multicentric Spanish Group of Clincally Localized Prostate Cancer: Montse Ferrer, Àngels Pont, Olatz Garin, Yolanda Pardo, Jordi Alonso, Mónica Ávila, Víctor Zamora, Ferran Guedea, Montse Ventura, Cristina Gutiérrez, Ferran Ferrer, Ana Boladeras, José Francisco Suárez, Manel Castells, Xavier Bonet, Pastor S, Carmen Bonet, Gemma Sancho, Javier Ponce de León, Joan Palou, Belén de Paula, Alai Goñi, Pablo Fernández, Ismael Herruzo, Asunción Hervás, Alfredo Ramos, Víctor Macías, Josep Solé, Marta Bonet, Alfonso Mariño, Patricia Cabrera, Maria José Ortiz